Caracterización clínica y demográfica de los pacientes con hipertensión arterial pulmonar o del grupo 1 y asociada a tromboembolismo pulmonar crónico atendidos en la Fundación Santa Fe de Bogotá durante el periodo 2017-2024

Vista sencilla de ítem
dc.contributor.advisorAguirre Rodríguez, Ángela Patricia
dc.contributor.authorSoto Camargo, Daniel Camilo
dc.contributor.authorBuitrago Sandoval, Andrés Felipe
dc.contributor.authorHernández Linares, Isabel Virgina
dc.contributor.authorAguirre Rodríguez , Angela Patricia
dc.contributor.orcidSoto Camargo, Daniel Camilo [0009-0008-1953-2126]
dc.contributor.orcidBuitrago Sandoval, Andrés Felipe [0000-0001-7693-0771]
dc.contributor.orcidHernández Linares, Isabel Virgina [0000-0002-6877-2555]
dc.contributor.orcidAguirre Rodríguez, Angela Patricia [0000-0001-7158-4347]
dc.date.accessioned2024-07-29T20:59:46Z
dc.date.available2024-07-29T20:59:46Z
dc.date.issued2024-07
dc.description.abstractLa hipertensión pulmonar es una patología potencialmente fatal, definida por el aumento de la presión en la arteria pulmonar por encima de 20 mmHg. A nivel mundial es considerada una patología de interés en salud pública, dada su alta carga de morbimortalidad y su impacto clínico. En la actualidad, las opciones terapéuticas que están disponibles en nuestro medio, a pesar de ser limitadas han demostrado efectividad clínica en la HAP de los grupos 1 y 4; sin embargo, es innegable la falta de estandarización diagnóstica y por ende de instauración oportuna de este tipo de terapias; esto derivado de la baja tasa diagnóstica y el importante subregistro que existe en nuestro medio. El objetivo de este estudio es determinar cuales son las características clínicas y demográficas de los pacientes con diagnóstico de hipertensión arterial pulmonar o del grupo 1 y asociada a tromboembolismo pulmonar crónico.
dc.description.abstractenglishPulmonary hypertension is a potentially fatal pathology, defined by an increase in pressure in the pulmonary artery above 20 mmHg. Worldwide, it is considered a pathology of public health interest, given its high burden of morbidity and mortality and its clinical impact. Currently, the therapeutic options that are available in our environment, despite being limited, have demonstrated clinical effectiveness in groups 1 and 4; However, the lack of diagnostic standardization and therefore timely installation of this type of therapies is undeniable; This is derived from the low diagnostic rate and the significant under-registration that exists in our environment. The objective of this study is to determine the clinical and demographic characteristics of patients diagnosed with pulmonary arterial hypertension or group 1 and associated with chronic pulmonary thromboembolism.
dc.description.degreelevelEspecializaciónspa
dc.description.degreenameEspecialista en Medicina Internaspa
dc.description.sponsorshipFundación Santa Fe de Bogotá
dc.format.mimetypeapplication/pdf
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlrepourl:https://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/12758
dc.language.isoes
dc.publisher.facultyFacultad de Medicinaspa
dc.publisher.grantorUniversidad El Bosquespa
dc.publisher.programEspecialización en Medicina Internaspa
dc.relation.references1. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J. 2022; ehac237.
dc.relation.references2. Zipes DP, Libby P, Bonow RO, Mann DL. Braunwald. Tratado de cardiología. 11th Vol. Elsevier, editor. Elsevier; 2019. 1699–1719 p.
dc.relation.references3. Goldman L, Schafer A, Goldman-cecil. Tratado de medicina interna. 26th ed. Elsevier, editor. Elsevier; 2020. 489–490 p.
dc.relation.references4. Mulder DS, Spicer J. Registry-Based Medical Research: Data Dredging or Value Building to Quality of Care? Ann Thorac Surg. 2019;108(1):274–82.
dc.relation.references5. Roos LL, Nicol PJ. A research registry: Uses, development, and accuracy. J Clin Epidemiol. 1999;52(1):39–47.
dc.relation.references6. Navarro-Pérez J, Franch-Nadal J, Artola-Menéndez S, Diez-Espino J, Garcia-Soidan J. La historia clínica electrónica y los registros sobre diabetes en España. Av en Diabetol. 2011;27(4):128–36.
dc.relation.references7. Hassoun PM. Pulmonary Arterial Hypertension. N Engl J Med. 2021;(385):2361–76.
dc.relation.references8. Sherman AE, Saggar R, Channick RN. Update on Medical Management of Pulmonary Arterial Hypertension. Cardiol Clin. 2022;40(1):13–27.
dc.relation.references9. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1).
dc.relation.references10. Zeder K, Banfi C, Steinrisser-Allex G, Maron BA, Humbert M, Lewis GD, et al. Diagnostic, prognostic and differential-diagnostic relevance of pulmonary haemodynamic parameters during exercise: a systematic review. Eur Respir J. 2022;60(4).
dc.relation.references11. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Pulmonary arterial hypertension in France: Results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023–30.
dc.relation.references12. Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K, et al. A global view of pulmonary hypertension. Lancet Respir Med. 2016;4(4):306–22.
dc.relation.references13. Vizza CD, Hoeper MM, Huscher D, Pittrow D, Benjamin N, Olsson KM, et al. Pulmonary Hypertension in Patients With COPD: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Chest. 2021;160(2):678–89.
dc.relation.references14. Rich S, Haworth SG, Hassoun PM, Yacoub MH. Pulmonary hypertension: the unaddressed global health burden. Lancet Respir Med. 2018;6(8):577–9.
dc.relation.references15. Moore LG, Niermeyer S, Zamudio S. Human Adaptation to High Altitude: Regional and Life-Cycle Perspectives. Yearb Phys Anthropol. 1998;41:25–64.
dc.relation.references16. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al. Predicting survival in pulmonary arterial hypertension: Insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation. 2010;122(2):164–72.
dc.relation.references17. Hoeper MM, Huscher D, Ghofrani HA, Delcroix M, Distler O, Schweiger C, et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry. Int J Cardiol. 2013;168(2):871–80.
dc.relation.references18. Hoeper MM, Pausch C, Grünig E, Staehler G, Huscher D, Pittrow D, et al. Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. Eur Respir J. 2022;59.
dc.relation.references19. Miranda PAM, Guzmán Sáenz RC, Ivan BA, Álvaro AB. Epidemiology of pulmonary hypertension in Colombia. Salud Uninorte. 2018;34(3):607–24.
dc.relation.references20. Price LC, Wort SJ, Perros F, Dorfmüller P, Huertas A, Montani D, et al. Inflammation in pulmonary arterial hypertension. Chest. 2012;141(1):210–21.
dc.relation.references21. Tuder R, Marecki J, Richter A, Fijalkowska I, Flores S. Pathology of Pulmonary Hypertension. Clin Chest Med. 2008;23(1):1–7.
dc.relation.references22. Southgate L, Machado RD, Gräf S, Morrell NW. Molecular genetic framework underlying pulmonary arterial hypertension. Nat Rev Cardiol. 2020;17(2):85–95.
dc.relation.references23. Ma L, Roman-Campos D, Austin ED, Eyries M, Sampson KS, Soubrier F, et al. A Novel Channelopathy in Pulmonary Arterial Hypertension. N Engl J Med. 2013;369(4):351–61.
dc.relation.references24. Austin ED, Ma L, LeDuc C, Rosenzweig EB, Borczuk A, Phillips JA, et al. Whole exome sequencing to identify a novel gene (Caveolin-1) associated with human pulmonary arterial hypertension. Circ Cardiovasc Genet. 2012;5(3):336–43.
dc.relation.references25. Long L, Ormiston ML, Yang X, Southwood M, Gräf S, Machado RD, et al. Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nat Med. 2015;21(7):777–85.
dc.relation.references26. Dong C, Zhou M, Liu D, Long X, Guo T, Kong X. Diagnostic accuracy of computed tomography for chronic thromboembolic pulmonary hypertension: A systematic review and meta-analysis. PLoS One. 2015;10(4):1–13.
dc.relation.references27. He J, Fang W, Lv B, He JG, Xiong CM, Liu ZH, et al. Diagnosis of chronic thromboembolic pulmonary hypertension: Comparison of ventilation/perfusion scanning and multidetector computed tomography pulmonary angiography with pulmonary angiography. Nucl Med Commun. 2012;33(5):459–63.
dc.relation.references28. Dumitrescu D, Nagel C, Kovacs G, Bollmann T, Halank M, Winkler J, et al. Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis. Heart. 2017;103(10):774–82.
dc.relation.references29. Hoeper MM, Pausch C, Olsson KM, Huscher D, Pittrow D, Grünig E, et al. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. Eur Respir J. 2022;60(1):1–12.
dc.relation.references30. Boucly A, Weatherald J, Savale L, de Groote P, Cottin V, Prévot G, et al. External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry. Eur Respir J. 2022;59(6).
dc.relation.references31. Rubin L, Badesch DB, Barst RJ. Bosentan therapy for pulmonary Arterial Hypertension. N Engl J Med. 2002;346(12):896–903.
dc.relation.references32. Casserly B, Klinger JR. Ambrisentan for the treatment of pulmonary arterial hypertension. Circulation. 2008;(2):265–80.
dc.relation.references33. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani H-A, et al. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. N Engl J Med. 2013;369(9):809–18.
dc.relation.references34. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. N Engl J Med. 2005;353(20):2148–57.
dc.relation.references35. Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119(22):2894–903.
dc.relation.references36. Ghofrani H-A, D’Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, et al. Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension. N Engl J Med. 2013;369(4):319–29.
dc.relation.references37. Ghofrani H-A, Galiè N, Grimminger F, Grünig E, Humbert M, Jing Z-C, et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2013;369(4):330–40.
dc.relation.references38. Barst RJ and R, Long LJ and, McGoon WA and, Rich MD and, Badesch S and, Groves DB and, et al. Conventional Therapy for Primary Pulmonary Hypertension. N Engl J Med. 1996;334(5):296–301.
dc.relation.references39. Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled Iloprost for Severe Pulmonary Hypertension. N Engl J Med. 2002;347(5):322–9.
dc.relation.references40. White RJ, Jerjes-Sanchez C, Meyer GMB, Pulido T, Sepulveda P, Wang KY, et al. Combination therapy with oral treprostinil for pulmonary arterial hypertension: A double-blind placebo-controlled clinical trial. Am J Respir Crit Care Med. 2020;201(6):707–17.
dc.relation.references41. Waxman A, Restrepo-Jaramillo R, Thenappan T, Ravichandran A, Engel P, Bajwa A, et al. Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. N Engl J Med. 2021;384(4):325–34.
dc.relation.references42. Conde-camacho RE, Rodriguez C. Metas en hipertensión pulmonar. Rev Colomb Cardiol. 2017;24:34–40.
dc.relation.references43. XVIII Congreso colombiano de neumología y cirugía de torax. Costos Médicos del Tratamiento Farmacológico en Pacientes con Hipertensión Arterial Pulmonar En Colombia 2019. XVIII Congreso colombiano de neumología y cirugía de torax. Vol. 31, Revista Colombiana de Neumología. 2019.
dc.relation.references44. Cassady S, Ramani G V. Right Heart Failure in Pulmonary Hypertension. Cardiol Clin. 2020;38(2):243–55.
dc.relation.references45. Naseem M, Alkassas A, Alaarag A. Tricuspid annular plane systolic excursion/pulmonary arterial systolic pressure ratio as a predictor of in-hospital mortality for acute heart failure. BMC Cardiovasc Disord. 2022;22(1):1–9.
dc.relation.references46. Tello K, Wan J, Dalmer A, Vanderpool R, Ghofrani HA, Naeije R, et al. Validation of the Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio for the Assessment of Right Ventricular-Arterial Coupling in Severe Pulmonary Hypertension. Circ Cardiovasc Imaging. 2019;12(9):1–11
dc.rightsAtribución-NoComercial-CompartirIgual 4.0 Internacionalen
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.localAcceso abiertospa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/
dc.subjectHipertensión arterial pulmonar
dc.subjectTromboembolismo pulmonar crónico
dc.subjectCateterismo cardíaco derecho
dc.subjectPresión arterial pulmonar media
dc.subjectResistencia vascular pulmonar
dc.subject.keywordsPulmonary arterial hypertension
dc.subject.keywordsChronic pulmonary thromboembolism
dc.subject.keywordsRight heart catheterization
dc.subject.keywordsMean pulmonary arterial pressure
dc.subject.keywordsPulmonary vascular resistance.
dc.subject.nlmWB 115
dc.titleCaracterización clínica y demográfica de los pacientes con hipertensión arterial pulmonar o del grupo 1 y asociada a tromboembolismo pulmonar crónico atendidos en la Fundación Santa Fe de Bogotá durante el periodo 2017-2024
dc.title.translatedClinical and demographic characterization of patients with pulmonary arterial hypertension or group 1 and associated with chronic pulmonary thromboembolism attended at Fundación Santa Fe in Bogotá during the period 2017-2024
dc.type.coarhttps://purl.org/coar/resource_type/c_7a1f
dc.type.coarversionhttps://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.driverinfo:eu-repo/semantics/bachelorThesis
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersion
dc.type.localTesis/Trabajo de grado - Monografía - Especializaciónspa

Archivos

Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
Trabajo de grado.pdf
Tamaño:
2.39 MB
Formato:
Adobe Portable Document Format
Descargar
Bloque de licencias
Mostrando 1 - 3 de 3
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.95 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
No hay miniatura disponible
Nombre:
Carta de autorización.pdf
Tamaño:
749.8 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
No hay miniatura disponible
Nombre:
Acta de grado.pdf.pdf
Tamaño:
172.58 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar

Colecciones

Especialización en Medicina Interna